ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

April 6, 2018: By Jon Swedien

ThromboGenicsThromboGenics’ candidate for diabetic macular edema (DME) was safe and well tolerated in a Phase I/II study, the Belgium company announced April 4.

The candidate, THR-317 (anti-PlGF), is a recombinant humanized monoclonal antibody directed against the receptor-binding site of human placental growth factor (PlGF), ThromboGenics said.

In preclinical models, anti-PlGF has been shown to be anti-inflammatory, in addition to anti-angiogenic and anti-edema, the company said.

The study enrolled 49 patients and included anti-VEGF naïve patients as well as sub-optimal anti-VEGF responders, ThromboGenics said.

Thirty percent of the anti-VEGF treatment naïve study subjects treated with THR-317 in the 8 mg group showed a greater than 15-letter gain from baseline at day 90 compared with 5.3 percent in the 4 mg group, the company said.

ThromboGenics said the data support a next study evaluating THR-317 in combination with an anti- VEGF, and the company hopes to initiate a clinical trial in Q2-2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023